

Cell Therapy

Part I: Technologies, Ethics & Regulations

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2021

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced and held academic positions in several countries including Switzerland, India, Iran, Germany Canada and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.

Prof. Jain's 490 publications include 35 books (6 as editor+ 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals, biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Contributions to MedLink, an accredited continuing education program for neurologists, include 172 articles out of a total of 1200 articles by 450 authors. These articles are updated on a yearly basis.

Prof. Jain's earlier books were the first in the areas covered: "Handbook of Laser Neurosurgery" (Charles C. Thomas, Springfield, Ill, 1983) and "Textbook of Hyperbaric Medicine" (1st ed in 1990 and 6th ed by Springer, 2017). His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Drug-induced Neurological Disorders", 4th ed (Springer 2021), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited 3 editions of "Drug Delivery System" (Springer 2008, 20012 and 2018) and "Applied Neurogenomics" (Springer 2015). Lectures on personalized medicine given at Kazakh National Medical University, Kazakhstan were translated into Russian and published as a book "Essentials of Personalized Medicine" (LITERRA Publishing House, Moscow, 2019). Currently, he is writing "The Handbook of Alzheimer Disease" to be published by Springer in 2022.

November 2021 (first edition published July 2001)
Copyright © 2021 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

T A B L E O F C O N T E N T S

0. Executive Summary	27
1. Introduction to Cell Therapy	31
Introduction	31
Historical landmarks of cell therapy	31
Interrelationship of cell therapy technologies	33
.....	34
Cells and organ transplantation	34
Cells and protein/gene therapy	34
.....	35
Cell therapy and regenerative medicine	35
Cell therapy and tissue engineering	36
Therapy based on cells involved in disease	37
Advantages of therapeutic use of cells	37
Synthetic cell therapy	37
Cell therapy as personalized medicine	38
Cell-based drug delivery	38
<i>Cells as vehicles for gene delivery</i>	38
<i>Red blood cells as vehicles for drug delivery</i>	39
<i>Advantages of cell-based drug delivery</i>	40
<i>Limitations of cell-based drug delivery</i>	41
2. Cell Therapy Technologies	43
Introduction	43
Cell types used for therapy	43
Sources of cells	43
Bone marrow	44
Blood component therapy	44
<i>Therapeutic apheresis</i>	44
<i>Leukoreduction</i>	45
<i>Platelet therapy</i>	45
<i>Red blood cell transfusion</i>	45
Cell lines	46
<i>Immortalized cells</i>	46
Xenografts	47
Basic technologies for cell therapy	47
Cell culture	47
<i>Automated cell culture devices</i>	47
<i>Cell culture for adoptive cell therapy</i>	48
<i>Observation of stem cell growth and viability</i>	48
<i>OpTmizer™ CTS™ T cell expansion tissue culture medium</i>	48
<i>Stem cell movement and behavior in culture</i>	48
<i>Companies involved in cell culture</i>	48
Cell sorting	50
<i>Flow cytometry</i>	50
<i>Applications of flow cytometry</i>	51
<i>A dielectrophoretic system for cell separation</i>	51
<i>Adult stem cell sorting by identification of surface biomarkers</i>	52
<i>ALDESORTER system for isolation of stem cells</i>	52
<i>Coulter principle-based cell sorters</i>	52
<i>Dynabead technology for cell sorting</i>	53
<i>Elutra® Cell Separation System</i>	53
<i>Magnetophoretic array-based cell sorting for further studies</i>	53
<i>Molecular beacons for specific detection and isolation of stem cells</i>	54
<i>Multitarget magnetic activated cell sorter</i>	54
<i>Nanocytometry</i>	54
<i>Scepter™ cytometer</i>	55
<i>Companies supplying cell sorters</i>	55
Cell analysis	56
<i>Cell analyzers</i>	56
<i>In vivo cell imaging</i>	56
<i>Measuring cell density</i>	57
<i>Measuring cell volume</i>	57
Single-cell gene expression analysis	57
<i>Fluorescent <i>in situ</i> RNA sequencing</i>	59
<i>Single-cell RNA sequencing of stem cells</i>	59
Preservation of cells	59

<i>Innovations in cryopreservation</i>	60
Packaging of cells	61
Selective expansion of T cells for immunotherapy	61
Cloning and cell therapy	62
Techniques for cell manipulation	62
Altering function of adult human cells	63
Cell-based drug discovery.....	63
Advantages and limitations of cell-based assays for drug discovery	63
<i>Advantages and limitations of cell-based toxicity screening</i>	64
<i>Quality control of cells for drug discovery</i>	64
Companies involved in cell-based drug discovery	64
Introduction of foreign materials into cells to develop therapeutics.....	66
Use of cell-penetrating peptides for intracellular transduction	66
Drug delivery systems for cell therapy	67
Intravenous delivery of stem cells.....	67
Intraarterial delivery of stem cells.....	67
Pharmacologically active microcarriers.....	67
Targeted delivery of engineered cells to specific tissues via circulation.....	68
Devices for delivery of cell therapy	68
Artificial cells.....	69
Applications of artificial cells.....	69
Cell encapsulation.....	70
Cell-in-a-Box®	70
Diffusion capsule for cells.....	71
Encapsulated cell biodelivery	71
Core-Shell Spherification.....	71
Ferrofluid microcapsules for tracking with MRI	72
Implantation of microencapsulated genetically modified cells	72
Nitric oxide delivery by encapsulated cells	72
Retrievable cell encapsulation device	73
Therapeutic applications of encapsulated cells	73
Companies involved in encapsulated cell technology	74
Electroporation	75
Gene therapy	76
Cell-mediated gene therapy	76
<i>Fibroblasts</i>	76
<i>Chondrocyte.....</i>	77
<i>Skeletal muscle cells</i>	77
<i>Vascular smooth muscle cells</i>	78
<i>Keratinocytes</i>	78
<i>Hepatocytes</i>	79
<i>Lymphocytes</i>	79
Cell-based CRISPR delivery	79
CRISPR-Edited Stem Cells	80
In vivo tracking of cells	80
Molecular imaging for tracking cells	80
<i>MRI technologies for tracking cells</i>	81
<i>Superparamagnetic iron oxide nanoparticles as MRI contrast agents</i>	82
<i>Survival of labeled hMSCs in regenerative therapy grafts</i>	82
<i>Visualization of gene expression in vivo by MRI</i>	82
Optogenetic monitoring of cell therapies	83
Role of nanobiotechnology in development of cell therapy	83
Nano-biocomposites containing living cells	84
Cell transplantation for development of organs	84
Cells transplantation and tolerance	84
Strategies to improve tolerance of transplanted cells	85
<i>Encapsulation to prevent immune rejection</i>	85
<i>Expansion of allospecific regulatory T cells</i>	85
<i>Prevention of rejection of xenotransplants.....</i>	86
Removal and replacement of pathogenic cells of the body.....	86
Therapeutic leukocytapheresis	86
3. Stem Cells.....	87
Introduction	87
Biology of stem cells.....	87
Embryonic stem cells.....	88
Growth and differentiation of ESCs.....	88
Mechanisms of differentiation of ESCs	89
<i>Chemical regulation of stem cell differentiation</i>	89
<i>In vitro differentiation of hESCs</i>	89
<i>SIRT1 regulation during stem cell differentiation</i>	90

Regulation of stem cell self-renewal and differentiation.....	90
<i>hESCs for reprogramming human somatic nuclei</i>	90
<i>Stem cells differentiation in the pituitary gland</i>	91
Influence of microenvironment on ESCs.....	91
Role of genes in differentiation of ESCs.....	91
<i>Global transcription in pluripotent ESCs</i>	91
<i>Role of p53 tumor suppressor gene in stem cell differentiation</i>	92
<i>Role of Pax3 gene in stem cell differentiation.....</i>	92
<i>Signaling pathways and ESC genes</i>	92
Epigenetics of hESCs	93
<i>Chromatin as gene regulator for ESC development.....</i>	94
Mechanism of regulation of stem cells for regeneration of body tissues.....	94
<i>Role of microenvironments in the regulation of stem cells</i>	94
<i>Regulation and regeneration of intestinal stem cells</i>	95
Parthenogenesis and human stem cells.....	95
<i>Uniparental ESCs</i>	96
<i>Haploid ESCs.....</i>	96
Bone marrow stem cells.....	97
Hematopoietic stem cells	97
<i>Clonal events that regulate HSC development</i>	99
<i>Derivation of HSCs from ESCs</i>	99
<i>Role of HSCs in the immune system</i>	99
Mesenchymal stem cells	99
<i>Cryopreservation of MSCs</i>	101
Multipotent adult progenitor cells	102
Side population stem cells.....	102
Differentiation of adult stem cells.....	103
Growth and differentiation of HSCs	104
<i>HSCs and aging</i>	104
<i>Mathematical modeling of differentiation of HSCs.....</i>	104
<i>Role of prions in self renewal of HSCs.....</i>	105
<i>Signaling pathways in the growth and differentiation of HSCs</i>	105
Sources of stem cells	105
Sources of of human embryonic stem cells.....	105
Nuclear transfer to obtain hESCs.....	106
Direct derivation of hESCs from embryos without nuclear transfer	107
Alternative methods of obtaining hESCs.....	107
<i>Establishing hESC lines without destruction of embryo.....</i>	107
<i>Altered nuclear transfer</i>	108
Advantages and disadvantages of ESCs for transplantation	109
Use of ESC cultures as an alternative source of tissue for transplantation	109
Spermatogonial stem cells	110
Very small embryonic-like stem cells	111
Amniotic fluid as a source of stem cells.....	111
<i>Amniotic fluid stem cells for tissue repair and regeneration</i>	111
<i>Generation of iPS cells from AF cells</i>	112
Placenta as source of stem cells.....	112
<i>Amnion-derived multipotent progenitor cells.....</i>	112
<i>Placenta as a source of HSCs.....</i>	113
<i>Umbilical cord as a source of MSCs</i>	113
Umbilical cord blood	114
<i>Applications of UCB</i>	114
<i>Advantages of UCB</i>	115
<i>Limitations of the use of UCB and measures to address them</i>	116
<i>Licensing and patent disputes involving UCB</i>	117
<i>Infections following UCB transplants</i>	117
<i>Unanswered questions about UCB transplantation</i>	118
<i>Companies involved in UCB banking</i>	118
<i>UCB banking in the UK</i>	119
<i>US national UCB banking system</i>	120
<i>Future of UCB.....</i>	121
UCB as source of stem cells.....	121
<i>Cryopreservation of UCB stem cells</i>	122
<i>Epigenetic programming for expansion of UCB cells.....</i>	122
<i>UCB as source of MSCs</i>	122
Techniques of nuclear reprogramming for stem cells	123
Induced pluripotent stem cells derived from human somatic cells	123
Characteristics of iPSCs	123
DNA methylation patterns of iPS cells	124
Techniques for obtaining iPSCs	124
iPSCs derived from skin	124

iPSCs derived through somatic cell nuclear transfer (SCNT).....	125
<i>iPSCs derived from oocytes</i>	125
<i>iPSCs derived from adult stem cells using SCNT</i>	125
iPSCs derived from blood	125
Use of CRISPR for generation of iPSCs.....	126
Use of retroviral vectors for generation of iPSCs	126
Use of non-integrating viral vectors for generation of iPSCs.....	127
Generation of other cells from iPSCs.....	127
<i>Generation of HCs from iPSCs</i>	127
<i>Generation of MSCs from iPSCs</i>	128
<i>Generation of RBCs from iPSCs</i>	128
Banks providing patient-specific iPSC lines	128
Center for iPS Cell Research Application.....	129
Companies providing iPSCs	129
Generation of clinically relevant iPSCs	130
<i>Equivalence of human iPSCs and ESCs</i>	130
<i>Genome editing and iPSCs</i>	131
<i>iPSCs and disease modeling</i>	131
<i>iPSCs for patient-specific regenerative medicine</i>	132
<i>Concluding remarks about clinical potential of iPSCs</i>	132
Induced conditional self-renewing progenitor cells	133
iXEN cells.....	133
Epiblast stem cells	134
Comparison of development of human and mouse ESCs	134
Conversion of hESCs to mouse ESC-like naïve states.....	134
Sources of adult human stem cells	135
Adipose tissue as a source of stem cells.....	135
<i>Encapsulation and hypothermic storage of adipose-derived stem cells</i>	135
<i>Intravenous infusion of adipose tissue derived MSCs</i>	136
<i>iPSCs derived from adult human adipose stem cells</i>	136
<i>Regulation of adipose stem cells differentiation</i>	136
<i>Transforming adult adipose stem cells into other cells</i>	137
Endometrium as a source of adult stem cells	137
Multipotent stem-like cells derived from vascular endothelial cells.....	137
Skin as a source of stem cells.....	138
<i>Controlling the maturation of embryonic skin stem cells</i>	138
<i>Epidermal neural crest stem cells</i>	138
<i>Follicle stem cells</i>	138
<i>Mesenchymal stem cells in skin</i>	139
<i>Regulation of stem cells in hair follicles</i>	139
<i>Skin-derived precursor cells</i>	140
Regulation of epidermal stem cells by circadian rhythms.....	140
Stem cells in teeth	140
Peripheral blood stem cells.....	141
Spleen as a source of adult stem cells	141
Search for master stem cells	142
Vascular cell platform to self-renew adult HSC.....	142
Adult stem cells vs embryonic stem cells	142
Biological differences between adult and embryonic stem cells	142
Neural crest stem cells from adult hair follicles	143
Transdifferentiation potential of adult stem cells	143
Attempts at stimulus-triggered acquisition of pluripotency	144
Limitations of adult stem cells	145
Pitfalls of pluripotency	145
Comparison of human stem cells according to derivation	146
VENT cells	146
ESC banking	146
Stem cell technologies	147
Analysis of stem cell growth and differentiation	147
Activation of bone marrow stem cells into therapeutic cells	147
Role of nitric oxide in stem cell mobilization and differentiation.....	147
Role of natriuretic peptide receptor-C in self-renewal of murine ESCs	148
Stem cell biomarkers.....	148
<i>Endoglin as a functional biomarker of HSCs</i>	148
<i>STEMPRO® EZChek™ for analysis of biomarkers of hESCs</i>	149
<i>SSEA-4 as biomarker of MSCs</i>	149
<i>p75NTR as a biomarker to isolate adipose tissue-derived stem cells</i>	149
<i>Neural stem cell biomarker</i>	149
<i>Protein expression profile as biomarker of stem cells</i>	150
<i>Real-time PCR for quantification of protein biomarkers</i>	150
Study of stem cell pathways.....	150

Stem cell genomics	151
<i>Gene expression in hESCs.....</i>	151
<i>Genomic alterations in cultured hESCs.....</i>	151
<i>Study of transcriptional regulation of stem cell genes</i>	152
<i>Casanova gene in zebrafish.....</i>	152
<i>Nanog gene.....</i>	152
Gene inactivation to study hESCs.....	153
<i>RNAi to study gene inactivation in hESCs</i>	153
<i>Study of ESC development by inducible RNAi.....</i>	154
<i>Targeting Induced Local Lesions in Genomes</i>	155
<i>Homologous recombination of ESCs.....</i>	155
Gene modification in genomes of hESCs and hiPSCs using zinc-finger nuclease.....	155
miRNA and stem cells.....	155
<i>Role of miRNAs in gene regulation during stem cell differentiation.....</i>	156
<i>Influence of miRNA on stem cell formation and maintenance.....</i>	156
<i>Restricted differentiation potential of miRNA-deficient PSCs.....</i>	157
<i>Transcriptional regulators of ESCs control miRNA gene expression</i>	157
Stem cells and cloning	157
<i>Cell nuclear replacement and cloning.....</i>	157
<i>Nuclear transfer and ESCs.....</i>	158
<i>Cloning from differentiated cells.....</i>	159
<i>Cloning mice from adult stem cells</i>	159
<i>Creating interspecies stem cells</i>	160
<i>Cloned cells for transplantation medicine</i>	160
<i>Claims of cloning of hESCs</i>	160
<i>hESCs derived by SCNT</i>	161
Cytogenetics of embryonic stem cells	162
Stem cell proteomics	163
<i>Comparative proteomic analysis of somatic cells, iPSCs and ESCs</i>	163
<i>hESC phosphoproteome.....</i>	163
<i>Proteomic studies of mesenchymal stem cells.....</i>	164
<i>Proteomic profiling of neural stem cells.....</i>	164
<i>Proteome Biology of Stem Cells Initiative</i>	164
Technologies for mobilization, expansion, and engraftment of stem cells	165
<i>Chemoattraction of neuronal stem cells through GABA receptor</i>	165
<i>Enhancement of HSC engraftment by calcium-sensing receptor</i>	166
<i>Ex vivo expansion of human HSCs in culture</i>	166
<i>Ex vivo expansion of MSCs.....</i>	167
<i>Ex vivo expansion of UCB cells for transplantation.....</i>	167
<i>Expansion of adult stem cells by activation of Oct4</i>	167
<i>Expansion of transduced HSCs in vivo</i>	168
<i>Expansion of stem cells in vivo by Notch receptor ligands</i>	168
<i>In vivo adipogenesis induced by adipose tissue-derived stem cells</i>	168
<i>Selective mobilization of progenitor cells from bone marrow.....</i>	168
<i>Selective Amplification.....</i>	169
<i>Synthetic substrates for ESC growth and expansion</i>	169
Technologies for inducing differentiation of stem cells.....	169
<i>Enhancement of stem cell differentiation by Homspera</i>	169
<i>Generation of RBCs from HSCs</i>	170
<i>Generation of multiple types of WBCs from hESCs and iPSCs.....</i>	170
<i>Growth factor-induced differentiation of MAPCs.....</i>	171
<i>Lineage selection to induce differentiation of hESCs.....</i>	171
<i>Mechanical strain to induce MSC differentiation.....</i>	171
<i>Neurotrophin-mediated survival and differentiation of hESCs.....</i>	171
<i>Synthetic biology and stem cells</i>	172
<i>Use of RNAi to expand the plasticity of autologous adult stem cells</i>	172
<i>Use of various molecules to induce differentiation of stem cells.....</i>	173
Limitations of the currently available stem cell lines in the US	173
Stem cell separation.....	173
Stem cell culture.....	174
<i>Culture of hMSCs</i>	175
<i>Elimination of contaminating material in stem cell culture</i>	175
<i>Long-term maintenance of MSC multipotency in culture.....</i>	176
<i>Nanofiber scaffolds for stem cell culture</i>	177
Conversion of stem cells to functioning adipocytes	177
Mass production of stem cells	178
<i>Mass production of ESCs.....</i>	178
<i>Mass production of MSCs</i>	178
Promoting survival of dissociated hESCs	178
Analysis and characterization of stem cells	178
Havesting and identification of EPCs	179

Labeling of stem cells	180
Labeling, imaging and tracking of stem cells in vivo	180
<i>Perfluorocarbon nanoparticles to track therapeutic cells in vivo</i>	180
<i>PET imaging for tracking of stem cells</i>	180
<i>Project for imaging in stem cell therapy research</i>	181
<i>Quantum dots for labeling and imaging of stem cells</i>	181
<i>Radiolabeling of MSCs for in vivo tracking</i>	182
<i>Superparamagnetic iron oxide nanoparticles for tracking MSCs</i>	182
<i>Tracking of transplanted muscle stem cells</i>	182
Applications of stem cells	182
Commercial development and applications of adult stem cells	183
<i>Preparation of cells for therapeutic administration to patients</i>	183
<i>Retrodifferentiation of stem cells</i>	184
<i>MultiStem</i>	184
Self renewal and proliferation of HSCs	184
Optimizing the preparation and transfer of allogeneic HSCs.....	185
Aging of stem cells.....	185
<i>Aging and rejuvenation of HSCs</i>	186
<i>Aging and MSCs</i>	186
iPSC-based modeling of late-onset age-related diseases	186
Peripheral blood stem cell transplantation	187
Role of stem cells in regeneration	187
<i>Pluripotent stem-cell-derived organoids</i>	187
<i>Promotion of regeneration by Wnt/beta-catenin signaling</i>	188
<i>Stem cell activation for regeneration by using glucocorticoids</i>	188
Stem cells and human reproduction	188
<i>Expansion of spermatogonial stem cells</i>	188
<i>Conversion of ESCs into spermatogonial stem cells</i>	189
<i>Conversion of stem cells to oocytes</i>	189
<i>ESCs for treatment of infertility in women</i>	190
<i>Cloning human embryos from oocytes matured in the laboratory</i>	190
<i>In utero stem cell transplantation</i>	191
Innovations in delivery of stem cells.....	192
<i>Polymeric capsules for stem cell delivery</i>	192
Immunological aspects of hESC transplantation	192
<i>Immunosuppression to prevent rejection of hESC transplants</i>	193
<i>Histocompatibility of hESCs</i>	193
<i>Strategies for promoting immune tolerance of hESCs</i>	193
Stem cells for organ vascularization	194
<i>Activation of EphB4 to enhance angiogenesis by EPCs</i>	195
Advantages and limitations of clinical applications of iPSCs	195
Advantages and limitations of clinical applications of MSCs.....	195
Biofusion by genetically engineering stem cells	196
Stem cell gene therapy	196
<i>Combination of gene therapy with nuclear transfer</i>	196
<i>Gene delivery to stem cells by artificial chromosome expression</i>	197
<i>Genetic manipulation of ESCs</i>	197
<i>Genetic engineering of human stem cells for enhancing angiogenesis</i>	197
<i>HSCs for gene therapy</i>	198
<i>iPSCs for targeted gene correction of α1-antitrypsin deficiency</i>	199
<i>Helper-dependent adenoviral vectors for gene transfer in ESCs</i>	199
<i>Lentiviral vectors for in vivo gene transfer to stem cells</i>	199
<i>Linker based sperm-mediated gene transfer technology</i>	199
<i>Mesenchymal stem cells for gene therapy</i>	200
<i>Microporation for transfection of MSCs</i>	200
<i>Regulation of gene expression for SC-based gene therapy</i>	200
<i>Stem cells and in utero gene therapy</i>	201
<i>Therapeutic applications for hematopoietic stem cell gene transfer</i>	201
<i>Targeted genome editing for human repopulating HSCs</i>	201
<i>The future of hematopoietic stem cell gene therapy</i>	202
Stem cell pharmaceutics	202
Pharmaceutical manipulation of stem cells	202
<i>Expansion of HSCs in culture by inhibiting aldehyde dehydrogenase</i>	203
<i>Expansion of HSCs in vivo by use of prostaglandin E2</i>	203
<i>Manipulation of stem cells with growth factors</i>	203
<i>Mobilization of stem cells by cytokines/chemokines</i>	205
<i>Mobilization of adult human HSCs by use of inhibitors</i>	206
<i>Mobilization of stem cells by HYC750</i>	207
<i>Mobilization of stem cells by hyperbaric oxygen</i>	207
<i>Mobilization by adenoviral vectors expressing angiogenic factors</i>	208
<i>Stem cell mobilization by acetylcholine receptor agonists</i>	208

<i>Use of parathyroid hormone to increase HSC mobilization</i>	208
<i>Use of small molecule compounds for expansion of HSCs</i>	208
<i>Use of a small molecule for targeting systemically infused MSCs</i>	209
Role of stem cells in therapeutic effects of drugs.....	209
Stem cells for drug discovery	209
<i>Target identification</i>	209
<i>High-throughput screening</i>	210
<i>ESCs as source of models for drug discovery</i>	210
<i>hESC-derived hepatocytes for drug discovery</i>	211
<i>hESC-derived cardiomyocytes for drug discovery</i>	211
<i>iPSCs for drug discovery</i>	212
<i>Advantages and limitations of use of stem cells for drug discovery</i>	213
Stem cells for drug delivery.....	213
Toxicology and drug safety studies using ESCs versus other cells.....	214
Future challenges for stem cell technologies	216
Generation of patient-specific pluripotent stem cells.....	216
Hybrid embryos/cybrids for stem cell research.....	217
In vivo study of human hemopoietic stem cells	217
Inhibition of stem cell-derived teratoma formation by small molecules	218
Markers for characterizing hESC lines	218
MBD3-deficient ESC line	218
Research into plasticity of stem cells from adults	219
Reversion of human stem cells to ground state pluripotency.....	219
Stem cell biology and cancer	219
Stem cells and aging	220
Stem cells in space	221
Study of the molecular mechanism of cell differentiation	222
Switch of stem-cell function from activators to repressors.....	222
Stem cell research at academic centers	223
International Regulome Consortium	224
Companies involved in stem cell technologies	224
Concluding remarks about stem cells	229
Future challenges in applications of stem cells	230
Challenges in research and development of stem cells	230
Challenges in the clinical use of pluripotent stem cells	231

4. Clinical Applications of Cell Therapy	233
Introduction	233
Cell therapy for hematological disorders	233
Transplantation of autologous hematopoietic stem cells	233
Cytomegalovirus infection after allogeneic HSC transplantation.....	233
<i>Lymphoproliferative disorders after allogeneic HSC transplants</i>	234
HSCs derived from pluripotent stem cells	234
Hemophilias	234
<i>Ex vivo cell/gene therapy of hemophilia B</i>	235
<i>Cell/gene therapy of hemophilia A</i>	235
Hematopoietic stem cell therapy for thrombocytopenia	236
Stem cell transplant for sickle cell anemia	236
Treatment of chronic acquired anemias.....	237
<i>Implantation of genetically engineered HSCs to deliver rhEpo</i>	237
<i>Drugs acting on stem cells for treatment of anemia</i>	237
Stem cell therapy of hemoglobinopathies	238
<i>iPSC-based therapy for β-thalassemia</i>	238
Stem cells for treatment of immunoglobulin-light chain amyloidosis	238
Future of cell therapy of hematological disorders	239
Cell therapy for immunological disorders	239
Role of natural killer cells in the immune system.....	239
Role of dendritic cells in the immune system	240
Modifying immune responses of DCs by vaccination with lipiodol-siRNA mixtures	240
Potential of MSCs as therapy for immune-mediated diseases	240
Stem cell therapy of chronic granulomatous disease.....	241
Stem cell therapy of X-linked severe combined immunodeficiency.....	241
Stem cell therapy of autoimmune disorders.....	241
<i>Wiskott-Aldrich Syndrome</i>	242
<i>Treatment of rheumatoid arthritis with stem cells</i>	242
<i>Treatment of Crohn's disease with stem cells</i>	243
<i>Stem cell transplants for scleroderma</i>	243
Role of T Cells in immunological disorders	244
<i>Autologous T cells from adult stem cells</i>	245
Cell therapy for graft vs host disease.....	245
<i>T cell infusion for suppressing GVHD</i>	246

<i>Genetically modified Tregs expressing CAR for prevention of GVHD</i>	246
<i>Concluding remarks on prevention and treatment of acute GVHD</i>	247
<i>MSCs for GVHD</i>	247
Cell therapy for viral infections	247
Anti-HIV ribozyme delivered in hematopoietic progenitor cells	247
Dendritic-cell targeted DNA vaccine for HIV	248
Exosomes and viral infections.....	248
Manipulation of T cells for treatment of viral infections	248
<i>T cell therapy for CMV</i>	248
<i>T cell therapy for HIV infection</i>	249
<i>T cell immunity by Overlapping Peptide-pulsed Autologous Cells</i>	249
Modification of iPSCs with a mutation to confer resistance to HIV.....	250
Cell therapy for COVID-19	250
Cell therapy of lysosomal storage diseases	250
Niemann-Pick disease.....	251
Gaucher's disease	251
Fabry's disease	252
Cell therapy for endocrine disorders	252
Hypopituitarism	252
Adrenal insufficiency	253
Cell therapy for diabetes mellitus	253
Limitations of current treatment	254
<i>Limitations of insulin therapy for diabetes mellitus</i>	254
<i>Limitations of pancreatic transplantation</i>	254
Islet cell transplantation	255
<i>Autologous pancreatic islet cell transplantation in chronic pancreatitis</i>	255
<i>Clinical trials of pancreatic islet cell transplants for diabetes</i>	255
<i>Drawbacks of islet cell therapy</i>	256
<i>Use of an antioxidant peptide to improve islet cell transplantation</i>	257
<i>Cdk-6 and cyclin D1 enhance human beta cell replication and function</i>	257
<i>Devices for delivery of therapeutic cells in diabetes</i>	257
<i>Monitoring of islet cell transplants with MRI</i>	258
<i>Concluding remarks about allogeneic islet transplantation for diabetes</i>	258
Encapsulation of insulin producing cells	258
<i>Encapsulated porcine pancreatic islet cells for pancreas</i>	258
<i>Encapsulated insulinoma cells</i>	259
<i>Magnetocapsule enables imaging/tracking of islet cell transplants</i>	259
Islet precursor cells.....	260
Dedifferentiation of β cells to promote regeneration	260
Pharmacological approaches for β cell regeneration.....	260
Xenotransplantation of embryonic pancreatic tissue	261
Non-pancreatic tissues for generation of insulin-producing cells	261
Exploiting maternal microchimerism to treat diabetes in the child	262
Bio-artificial substitutes for pancreas	262
Role of stem cells in the treatment of diabetes	263
<i>Embryonic stem cells for diabetes</i>	263
<i>HSC transplantation to supplement immunosuppressant therapy</i>	264
<i>Insulin-producing cells derived from UCB stem cells</i>	264
<i>iPSC for diabetes</i>	265
<i>Pancreatic stem cells</i>	265
<i>Pluripotent stem cell-derived pancreatic β-like cells</i>	266
<i>Stem cell injection into portal vein of diabetic patients</i>	266
Conversion of progenitor cells into insulin-producing cells	266
<i>Human neural progenitor cells converted into insulin-producing cells</i>	266
<i>Isolation of islet progenitor cells</i>	266
<i>Pancreatic progenitor cells</i>	267
Cell-based immunotherapy for type 1 diabetes	267
<i>Dendritic cell-based therapy</i>	267
<i>T regulatory cell therapy for diabetes</i>	268
<i>Vaccine for diabetes</i>	268
Synthetic biomimetic β -cells for dynamic insulin secretion.....	268
Gene therapy in diabetes	269
<i>Viral vectors for gene therapy of diabetes</i>	269
<i>Genetically engineered dendritic cells</i>	269
<i>Genetically altered liver cells</i>	270
<i>Genetically modified stem cells</i>	270
Companies developing cell therapy for diabetes	270
Concluding remarks about cell and gene therapy of diabetes	271
Cell therapy of gastrointestinal disorders	272
Inflammatory bowel disease.....	273
Cell therapy for liver disorders	273

Types of cells used for hepatic disorders	273
<i>Culture and expansion of primary human hepatocytes</i>	273
<i>Hepatocyte progenitor cells</i>	274
<i>Hybrid periportal hepatocytes</i>	274
Methods of delivery of cells for hepatic disorders	275
Hepatic failure	275
Bioartificial liver	275
<i>Hepatocyte-based artificial liver</i>	276
<i>Extracorporeal Liver Assist Device</i>	276
<i>Limitations of bioartificial liver</i>	276
<i>Proliferating cell-based bioartificial liver</i>	276
Stem cells for hepatic disorders	277
<i>Deriving hepatocytes from commercially available hMSCs</i>	278
<i>Implantation of hepatic cells derived from hMSCs of adipose tissue</i>	278
<i>Heterologous adult liver progenitor cells</i>	278
<i>Liver stem cell culture</i>	278
<i>MSC derived molecules for reversing hepatic failure</i>	279
Cell-based gene therapy for liver disorders.....	279
<i>Transplantation of genetically modified fibroblasts</i>	280
<i>Transplantation of genetically modified hepatocytes</i>	280
<i>Genetically modified hematopoietic stem cells</i>	280
<i>iPSCs derived from somatic cells for liver regeneration</i>	280
<i>Hepatocyte-like cells derived from human parthenogenetic stem cells</i>	281
Clinical applications.....	281
Future prospects of cell-based therapy of hepatic disorders.....	282
Cell therapy of renal disorders.....	282
Bioartificial kidney.....	282
Cell-based repair for vascular access failure in renal disease	283
Mesangial cell therapy for glomerular disease.....	283
Stem cells for renal disease.....	284
<i>Role of stem cells in renal repair</i>	284
<i>Bone marrow stem cells for renal disease</i>	284
<i>Human amniotic fluid stem cells for renal regeneration</i>	285
<i>MSC therapy for renal disease</i>	285
<i>MSCs as aid to renal graft survival</i>	285
Transplantation of cell-based bioengineered kidney	286
Cell therapy for pulmonary disorders.....	286
Delivery of cell therapy for pulmonary disorders	286
<i>Intratracheal injection of cells for pulmonary hypoplasia</i>	286
Role of stem cells in pulmonary disorders	287
<i>Lung stem cells</i>	287
<i>Lung tissue regeneration from stem cells</i>	287
<i>MSC transplantation in patients with COVID-19 pneumonia</i>	288
<i>Role of autologous MSCs in the treatment of severe emphysema</i>	288
<i>Role of stem cells in construction of the Cyberlung</i>	288
<i>Respiratory epithelial cells derived from UCB stem cells</i>	288
<i>Respiratory epithelial cells derived from hESCs</i>	289
<i>Lung tissue engineering with adipose stromal cells</i>	289
<i>Cell-based tissue-engineering of airway</i>	290
Pulmonary disorders that can be treatable with stem cells	290
<i>Acute lung injury and ARDS treated with MSCs</i>	291
<i>Bronchopulmonary dysplasia treated with MSCs</i>	292
<i>Chronic obstructive pulmonary disease treated with MSCs</i>	292
<i>Cystic fibrosis treatment with genetically engineered MSCs</i>	293
<i>Idiopathic pulmonary fibrosis</i>	294
<i>Lung regeneration by integrin α6β4-expressing alveolar epithelial cell</i>	294
<i>Pulmonary arterial hypertension treatment with EPCs</i>	294
Cell therapy for disorders of bones, joints and tendons	295
Cell therapy for repair of fractures and bone defects	295
<i>Bone regeneration by human very small embryonic-like (hVSEL) cells</i>	296
<i>Cell therapy for cervical vertebral interbody fusion</i>	296
<i>Cell-mediated gene therapy for bone regeneration</i>	296
<i>ESCs for bone repair</i>	297
<i>hiPSCs for engineering personalized bone grafts</i>	297
<i>Intrauterine use of MSCs for osteogenesis imperfecta</i>	297
<i>In vivo bone engineering as an alternative to cell transplantation</i>	297
<i>In vivo differentiation of pluripotent stem cells for bone regeneration</i>	298
<i>MSCs for repair of bone defects</i>	298
<i>MSCs for repair of bone fractures</i>	301
<i>Osteocel</i>	302
<i>Stem cells for repairing skull defects</i>	302

<i>Stem cell-based bone tissue engineering</i>	302
<i>Spinal fusion using stem cell-based bone grafts.....</i>	303
<i>Wnt stimulation to enrich BMMCs for repair of bone fractures</i>	304
Cell therapy of tendon injuries.....	304
<i>Autologous tenocyte implantation in rotator cuff injury repair.....</i>	304
<i>Platelet injection for tennis elbow.....</i>	305
Cell-based techniques for cartilage repair and regeneration.....	305
<i>Cartilage generation from stem cells</i>	305
<i>Cartilage engineering from iPSCs</i>	307
<i>Genetically modified fibroblasts expressing TGF-β for cartilage repair</i>	307
<i>Juvenile cartilage implant for repair of damage to articular cartilage.....</i>	307
Cell therapy for repair of knee cartilage injuries.....	308
<i>Autologous chondrocyte therapy of the knee</i>	309
<i>Meniscus-derived stem cells</i>	309
<i>MSC-based constructs for knee joint replacement</i>	309
<i>Nanobiotechnology scaffolds for MSC-based cartilage reconstruction</i>	310
<i>Role of cells in the repair of anterior cruciate ligament injury.....</i>	310
Osteoporosis	311
<i>Stem cell gene therapy for osteoporosis.....</i>	311
Osteoarthritis of the joints	311
<i>Autologous cultured chondrocytes</i>	312
<i>Autologous intervertebral disc chondrocyte transplantation</i>	313
<i>Intraarticular MSCs for osteoarthritis</i>	314
<i>Mosaicplasty.....</i>	314
<i>Stem cell therapy of osteoarthritis of the knee.....</i>	314
Osteonecrosis.....	315
<i>Cell therapy for osteonecrosis.....</i>	315
<i>Cell therapy for radionecrosis</i>	315
<i>Repair of osteonecrosis by bone marrow derived MSCs</i>	315
Rheumatoid arthritis.....	315
Cell therapy for diseases of the eye	316
Age-related macular dystrophy	316
Cell therapy for corneal repair	316
Use of human cultured endothelial cells for bullous keratopathy.....	318
Lens regeneration from endogenous stem cells.....	318
Role of stem cells in fibrosis following eye injury	319
Stem cell therapy for limbal stem cell deficiency	319
Stem cell transplantation for radiation sickness	320
MSCs for treatment of radiation damage to the bone.....	320
MSCs for regeneration of ovaries following radiotherapy damage	320
Cell therapy for wound healing.....	320
Cells to form skin substitutes for healing ulcers	321
CellSpray for wound repair.....	322
Cell therapy for burns.....	322
Closure of incisions with laser guns and cells	323
Genetically engineered keratinocytes for wound repair	323
MSCs for wound healing.....	324
Role of amniotic fluid MSCs in repair of fetal wounds	324
Treatment of diabetic foot ulcers with stem cells.....	324
Role of cells in regenerative medicine	324
Stem cells for regeneration of skin and appendages	325
<i>Bifunctional ectodermal stem cells and nail regeneration.....</i>	325
<i>Stem cells for regeneration of skin in junctional epidermolysis bullosa.....</i>	325
<i>Follicular stem cells for skin and wound repair.....</i>	325
<i>Regeneration of aging skin by adipose-derived stem cells</i>	326
<i>Reprogramming autologous stem cells for regeneration of skin</i>	326
<i>Concluding remarks on regeneration of skin by stem cells</i>	327
Cell therapy for regeneration of muscle wasting	327
Role of stem cells in regeneration of esophageal epithelium	328
Stem cell-based regenerative therapy for xerostomia	328
Concluding remarks for use of cells in regenerative medicine.....	328
<i>Genomic studies for examining the role of stem cells in regeneration</i>	328
<i>Cell therapy for regenerating organs</i>	329
<i>MSCs for regenerative medicine</i>	330
<i>Umbilical cord blood for regeneration</i>	330
Future prospects of stem cells for regenerative medicine	330
Role of cells in tissue engineering and reconstructive surgery	331
Scaffolds for tissue engineering	331
Improving vascularization of engineered tissues	331
<i>Reconstruction of vasculature</i>	331
Repair of aging skin by injecting autologous fibroblasts	332

Enhancing vascularization by combining cell and gene therapy	332
Nanobiotechnology applied to cells for tissue engineering	333
Choosing cells for tissue engineering	333
Stem cells for tissue repair.....	334
<i>ESCs vs adult SCs for tissue engineering.....</i>	334
<i>Use of adult MSCs for tissue engineering.....</i>	335
<i>Measuring MSC interactions with environment for tissue engineering.....</i>	335
Stem cells for tissue engineering of various organs	336
<i>Breast reconstruction by adipose tissue-derived stem cells.....</i>	336
<i>Engineering of healthy living teeth from stem cells.....</i>	336
<i>Intra-uterine repair of congenital defects using amniotic fluid MSCs</i>	337
<i>Skin regeneration by stem cells as an alternative to face transplant</i>	338
<i>Tissue engineering of bone by stem cells</i>	338
Cell-based tissue engineering in genitourinary system	339
<i>Urinary incontinence.....</i>	339
<i>Tissue engineering of urinary bladder.....</i>	340
<i>Label retaining urothelial cells for bladder repair</i>	341
<i>MSCs for bladder repair</i>	341
<i>Tissue-engineering of urethra using autologous cells</i>	341
<i>Repair of the pelvic floor with stem cells from the uterus</i>	342
<i>Reconstruction of vagina from stem cells</i>	342
Reconstruction of cartilage for repair of craniofacial defects.....	342
Intraoperative cell therapy	342
Cell therapy for rejuvenation	343
Reversal of muscle weakness and atrophy in aging	343
Reversal of cognitive impairment in aging	344
Treatment of frailty of aging with MSCs	344
Cell therapy for performance enhancement in sports	344
Application of stem cells in veterinary medicine	345
Stem cells for repair of tendon injuries in horses.....	345
Stem cells for spinal cord injury in dogs.....	346
Stem cells for arthritis in horses	346
5. Cell Therapy for Cardiovascular Disorders	347
Introduction to cardiovascular disorders	347
Limitations of current therapies for myocardial ischemic disease.....	347
Types of cell therapy for cardiovascular disorders.....	347
Cell-mediated immune modulation for chronic heart disease	349
Inducing the proliferation of cardiomyocytes	349
Pericardial origin of colony-forming units	350
Role of splenic myocytes in repair of the injured heart	350
Reprogramming of fibroblasts into functional cardiomyocytes	350
Stem cell-based therapies for cardiovascular diseases	351
<i>Human cardiovascular progenitor cells.....</i>	351
<i>Human pluripotent stem cell-derived cardiomyocytes</i>	352
<i>Large cardiac-muscle patches based on hiPSC technology</i>	352
<i>Magnetic antibody-linked nanoparticles to deliver cells to the heart.....</i>	352
<i>Role of the SDF-1-CXCR4 axis in therapies for myocardial ischemia.....</i>	352
<i>Small molecules to enhance myocardial repair by stem cells.....</i>	353
<i>Stem cells and atherosclerosis.....</i>	353
Cell therapy for atherosclerotic coronary artery disease.....	354
<i>MyoCell™ (Bioheart).....</i>	354
Cardiac stem cells	354
Cardiomyocytes derived from epicardium	355
Cardiac atrial appendage stem cells	356
Methods of delivery of cells to the heart	356
Cellular cardiomyoplasty	356
IGF-1 delivery by nanofibers to improve cell therapy for MI.....	357
Non-invasive delivery of cells to the heart by Morph@guide catheter	357
Cell therapy for cardiac revascularization	357
Transplantation of cardiac progenitor cells for revascularization of myocardium	357
Stem cells to prevent restenosis after coronary angioplasty	358
Role of cells in cardiac tissue repair.....	358
Cardiac repair with myoendothelial cells from skeletal muscle	358
Modulation of cardiac macrophages for repair of infarct	359
Multipotent cells from placenta for regeneration of the heart	359
Myocardial tissue engineering	359
Patching myocardial infarction with fibroblast culture	360
Transplantation of myoblasts for myocardial infarction.....	361
Role of stem cells in repair of the heart	361
Role of stem cells in cardiac regeneration following injury	361

Cardiomyocytes derived from adult skin cells	362
Cardiomyocytes derived from ESCs	362
Cardiomyocyte differentiation from hIPSCs	364
Studies to identify subsets of progenitor cells suitable for cardiac repair	364
Technologies for preparation of stem cells for cardiovascular therapy	364
<i>Pravastatin for expansion of endogenous progenitor and stem cells.</i>	364
<i>Cytokine preconditioning of human fetal liver CD133+ SCs</i>	365
<i>Expansion of adult cardiac stem cells for transplantation.</i>	365
<i>Role of MSCs in growth of CSCs</i>	366
Role of ESCs in repair of the heart	366
<i>ESC transplantation for tumor-free repair of the heart</i>	367
Transplantation of stem cells for myocardial infarction	367
<i>Autologous bone marrow-derived stem cell therapeutics</i>	367
<i>Autologous bone marrow-derived mesenchymal precursor stem cells</i>	368
<i>Intracoronary infusion of mobilized peripheral blood stem cells</i>	368
<i>Transplantation of cord blood stem cells</i>	369
<i>Transplantation of hESCs</i>	369
<i>Transplantation of HSCs</i>	369
<i>Transplantation of autologous angiogenic cell precursors</i>	370
<i>Transplantation of adipose-derived stem cells</i>	370
<i>Transplantation of bone marrow-derived cells for myocardial infarct</i>	371
<i>Transplantation of human umbilical cord perivascular cells</i>	372
<i>Transplantation of endothelial cells</i>	372
<i>Transplantation of cardiomyocytes differentiated from hESCs</i>	373
Stem cell therapy for cardiac regeneration	373
<i>3D printed scaffold for regeneration of myocardial infarct with cells</i>	373
<i>Cryopreserved hESC-derived cardiomyocytes for cardiac regeneration</i>	374
<i>Exosomal miRNAs from hiPSC-derived cardiomyocytes</i>	374
<i>HSCs for regeneration of the chronic myocardial infarcts</i>	374
<i>Human MSCs for cardiac regeneration</i>	374
<i>In vivo tracking of MSCs transplanted in the heart</i>	375
<i>MSCs for hibernating myocardium</i>	376
<i>Simultaneous transplantation of MSCs and skeletal myoblasts</i>	376
<i>Transplantation of stem cells and immune response of the heart</i>	376
Transplantation of genetically modified cells.....	377
Transplantation of genetically modified MSCs	377
Transplantation of cells secreting vascular endothelial growth factor	377
Transplantation of genetically modified bone marrow stem cells.....	377
Cell transplantation for congestive heart failure.....	377
AngioCell gene therapy for congestive heart failure	378
Injection of adult stem cells for CHF	379
Intracoronary infusion of cardiac stem cells.....	379
Myoblasts for treatment of congestive heart failure	379
Stem cell therapy for dilated cardiac myopathy.....	380
Role of cell therapy in cardiac arrhythmias.....	380
Biological pacemakers	381
<i>Stem cells as biological pacemakers</i>	381
<i>Stem cells for cardiac arrhythmias</i>	382
Prevention of myoblast-induced arrhythmias by genetic engineering	382
Ventricular tachycardia	382
ESCs for correction of congenital heart defects	383
Cardiac progenitors cells for treatment of heart disease	383
Autologus stem cells for chronic myocardial ischemia	384
Role of cells in cardiovascular tissue engineering.....	384
Cell-based in vitro regeneration of heart for transplantation	384
Construction of blood vessels with cells	385
<i>Engineered arteries for bypass grafts</i>	385
Engineering heart valves with UCB progenitor cells	386
Epicardial regeneration from hPSCs.....	386
Fetal cardiomyocytes seeding in tissue-engineered cardiac grafts.....	386
Targeted delivery of endothelial progenitor cells labeled with nanoparticles	387
Cell therapy for peripheral vascular disease	387
ALD-301	387
Cell/gene therapy for PVD.....	387
Cell therapy for CLI in diabetics	388
Colony stimulating factors for enhancing peripheral blood stem cells	388
Intramuscular autologous bone marrow cells.....	388
Ixmyelocel-T cell therapy for critical limb ischemia.....	389
Stem cell-coated vascular grafts for femoral-tibial arterial bypass	389
Clinical trials of cell therapy in cardiovascular disease	389
Mechanism of the benefit of cell therapy for heart disease	392

A critical evaluation of cell therapy for heart disease	392
Publications of clinical trials of cell therapy for CVD	393
Current status of cell therapy for cardiovascular disease	393
Future directions for cell therapy of CVD	394
Combination of cells with biomedical scaffolds	394
Prospects of adult stem cell therapy for repair of heart	394
Role of cells in regeneration of the heart.....	395
Regeneration of cardiomyocytes without use of cardiac stem cells.....	395
6. Cell Therapy for Cancer.....	397
Introduction	397
Cell therapy technologies for cancer	397
Cell-based delivery of anticancer therapy	398
Cellular immunotherapy for cancer	398
Treatments for cancer by ex vivo mobilization of immune cells	399
Granulocytes as anticancer agents	399
Neutrophil granulocytes in antibody-based immunotherapy of cancer	400
Cancer vaccines	400
Autologous tumor cell vaccines	400
<i>BIOVAXID</i>	400
<i>OncovAX</i>	401
<i>Tumor cells treated with dinitrophenyl</i>	401
Vaccines that simultaneously target different cancer antigens	401
Gene modified cancer cells vaccines	402
<i>GVAX cancer vaccines</i>	402
<i>K562/GM-CSF</i>	402
Active immunotherapy based on antigen specific to the tumor.....	403
The use of dendritic cells for cancer vaccination	403
<i>Autologous dendritic cells loaded ex vivo with telomerase mRNA</i>	403
<i>Dendritic cell-targeted protein vaccines</i>	404
<i>Dendritic/tumor cell fusion</i>	404
<i>Electro-hyperthermia for improving DC immunotherapy</i>	404
<i>Genetically modified dendritic cells</i>	405
<i>In vivo manipulation of dendritic cells</i>	405
<i>Preclinical and clinical studies with DC vaccines</i>	405
<i>Vaccines based on dendritic cell-derived exosomes</i>	406
<i>Limitations of DC vaccines for cancer.</i>	406
<i>Future developments to enhance clinical efficacy of DC vaccines</i>	407
Cell-based cancer immunotherapy	408
<i>Adoptive cell therapy</i>	408
<i>CD8+ T cells for use in tumor immunotherapy</i>	409
<i>Combination of antiangiogenic agents with ACT</i>	410
<i>Expansion of antigen-specific cytotoxic T lymphocytes</i>	411
<i>Genetically modified T cells for targeting tumors</i>	411
<i>Genetic engineering of tumor cells to activate T helper cells</i>	411
<i>Targeting T regulatory cells</i>	412
<i>T cells with immunological memory and stem cell-like properties</i>	412
<i>T cell imaging for predicting response to cancer vaccines</i>	412
<i>Tumor infiltrating lymphocytes</i>	413
Chimeric antigen receptor T cells	413
<i>Basics of CAR-T cell</i>	413
<i>Basis of anticancer effect of CAR-T cells</i>	414
<i>CAR-T cell manufacture</i>	414
<i>CAR-T cell therapy for leukemia</i>	415
<i>CAR-T cell therapy for multiple myeloma</i>	416
<i>CAR-T cell therapy for lymphoma</i>	416
<i>CAR-T cell therapy for solid tumors</i>	417
<i>CAR-T cell therapy for cardiac fibrosis</i>	418
<i>Companies developing CAR-T cell therapy</i>	418
<i>CAR NK cells derived from human iPSCs</i>	421
<i>Genome editing of CAR-T cells</i>	421
<i>ProCAR-NK cancer immunotherapy</i>	422
<i>Remote control of CAR-T cells</i>	422
<i>Safety of CAR-T cell therapy</i>	422
<i>Concluding remarks and future of T-cell therapy</i>	424
Chemoimmunotherapy	424
Hybrid cell vaccination	425
Stem cell-based anticancer therapies	425
Stem cell transplantation in cancer.....	425
<i>Peripheral blood stem cell transplantation</i>	425
<i>Stem cell transplantation for hematological malignancies</i>	428

<i>Long-term results of HSC transplantation</i>	429
<i>Prediction of T cell reconstitution after HSC transplantation</i>	430
<i>HSC transplantation followed by GM-CSF-secreting cell vaccines</i>	430
<i>HSC transplantation for renal cell cancer</i>	430
<i>Umbilical cord blood transplant for hematological malignancies</i>	431
Complications of stem cell transplants in cancer	432
<i>Graft-versus-host disease (GVHD)</i>	432
<i>Delayed immune reconstitution leading to viral infections and relapse</i>	432
<i>Tumor cell contamination</i>	433
<i>Neurological complications</i>	433
<i>Hepatic veno-occlusive disease</i>	434
<i>Current status and safety of allogeneic HSC transplantation</i>	434
<i>Complications of PBSC transplantation in children</i>	435
Role of MSCs in cancer	435
<i>MSC-mediated delivery of anticancer therapeutics</i>	435
<i>Mesenchymal progenitor cells for delivery of oncolytic adenoviruses</i>	436
<i>MSCs for oncolytic HSV delivery for brain metastases of melanoma</i>	436
Nonmyeloablative allogeneic hematopoietic stem cell transplantation	436
hESC-derived NK cells for treatment of cancer	437
ESC vaccine for prevention of lung cancer	437
Genetic modification of stem cells for cancer therapy	438
<i>Genetic modification of hematopoietic stem cells</i>	438
<i>Use of hematopoietic stem cells to deliver suicide genes to tumors</i>	438
<i>Delivery of anticancer agents by genetically engineered MSCs</i>	438
<i>Genetically modified NSCs for treatment of neuroblastoma</i>	439
Innovations in cell-based therapy of cancer	440
Use of immortalized cells	440
Cancer therapy based on natural killer cells	440
Cytokine-induced killer cells	440
Mesothelin as a target for cancer immunotherapy	441
Nanomagnets for targeted cell-based cancer gene therapy	441
Implantation of genetically modified encapsulated cells for anticancer therapy	441
<i>Antiangiogenesis therapy by implantation of microencapsulated cells</i>	441
<i>Recombinant tumor cells secreting fusion protein</i>	442
<i>A device for filtering cancer and stem cells in the blood</i>	442
Cancer stem cells	442
<i>Cancer stem cell biomarkers</i>	443
<i>Integrative nuclear signaling and development of cancer in stem cells</i>	443
<i>Origin of cancer in normal stem cells</i>	443
<i>Role of intestinal stem cells in intestinal polyposis</i>	444
<i>Role of endothelial progenitor cells in tumor angiogenesis</i>	444
<i>Role of cancer stem cells in metastases</i>	444
<i>Role of cancer stem cells in chemotherapy</i>	445
<i>Therapeutic implications of cancer stem cells</i>	445
<i>Targeting breast cancer stem cells</i>	446
<i>Targeting cancer stem cells in leukemia</i>	446
<i>Targeting cancer stem cells in ovarian cancer</i>	447
<i>Targeting cancer stem cells to screen anticancer drugs</i>	447
Companies involved in cell-based cancer therapy	448
American Association for Cancer Research and ESCs	449
Future of cell-based immunotherapy for cancer	449
7. Cell Therapy for Neurological Disorders	451
Introduction	451
Use of stem cells for research in neurosciences	451
Cerebral organoids for modeling human brain development	451
Use of human stem cell-derived neurons in neuropharmacology	451
Regeneration of brain by in vitro/in vivo reprogramming of cells	452
Molecular mechanism of neurogenesis	453
Generation of neurons from astroglia	454
In vivo cell replacement therapy by locally induced neural progenitor cells	454
In vivo reprogramming to generate new neurons	454
Types of cells used for treatment of neurological disorders	455
Activated T lymphocytes	456
Differentiation of placenta-derived multipotent cells into neurons	456
Fibroblast-derived human striatal neurons	456
Mesenchymal stem cells induced to secrete neurotrophic factors	456
MUSE cells transplantation for neuronal regeneration	457
Neural stem cells	457
<i>Development of human CNS stem cells</i>	457
<i>Direct conversion of adult fibroblasts into neural progenitor cells</i>	458

<i>Distinction between NSCs and intermediate neural progenitors</i>	458
<i>Embryonic stem cell-derived neurogenesis.....</i>	458
<i>Epidermal neural crest stem cells for neurological disorders</i>	459
<i>Fusion of NSCs with endogenous neurons</i>	459
<i>Induction of NSCs from hESCs.....</i>	459
<i>Induction of NSCs from adult MSCs</i>	461
<i>Mechanism of migration of NSCs to sites of CNS injury</i>	461
<i>Monitoring of implanted NSCs labeled with nanoparticles</i>	461
<i>Neural progenitor cells.....</i>	461
<i>Neural stem cells in the subventricular zone of the brain.....</i>	464
<i>Neural stem cells derived from induced neural plate border stem cells.....</i>	464
<i>Oligodendrocyte progenitor cells</i>	464
<i>Promotion of neural stem cells expansion by betacellulin</i>	464
<i>Proteomics of neural stem cells.....</i>	465
<i>Regulation of neural stem cells in the brain</i>	465
<i>Role of CSF in regulation of neural progenitor cells.....</i>	466
<i>Sequencing the transcriptomes of neural stem cells</i>	467
<i>Study of neural differentiation of hESCs by NeuroStem Chip.....</i>	467
<i>Transformation of neural stem cells into other cell types.....</i>	467
Stem cell transplantation in the CNS	468
<i>Development of CNS cells from non-CNS stem cells</i>	468
<i>Expansion of adult human neural progenitors</i>	468
<i>Hair-follicle stem cells for neural repair.....</i>	469
<i>Human NSCs for treatment of neurological disorders</i>	469
<i>NSCs and scaffolds for regeneration therapy of CNS disorders</i>	470
<i>Neurospheres</i>	470
<i>Stem cells from olfactory epithelium for transplantation in the CNS.....</i>	471
<i>Stem cells from human umbilical cord blood for CNS disorders</i>	471
<i>Choroid plexus cells for transplantation.....</i>	471
<i>Dental pulp cells for neuroprotection</i>	472
<i>Derivation of CNS cells from peripheral nervous system.....</i>	472
<i>Fetal tissue transplants.....</i>	472
<i>Immortalized cells for CNS disorders</i>	473
<i>Laboratory mice with human brain cells</i>	474
<i>Olfactory ensheathing cells for CNS repair.....</i>	474
<i>Ideal cells for transplantation into the nervous system</i>	474
Cell therapy techniques for neurological applications	475
<i>Carbon nanotubes to aid stem cell therapy of neurological disorders</i>	475
<i>Cell transplantation for regeneration of the nervous system</i>	475
<i>Cells used for gene therapy of neurological disorders.....</i>	475
<i> <i>Fibroblasts</i></i>	476
<i> <i>Stem cells.....</i></i>	476
<i> <i>Neuronal cells.....</i></i>	476
<i> <i>Immortalized neural progenitor cells</i></i>	476
<i> <i>Astrocytes.....</i></i>	477
<i> <i>Cerebral endothelial cells</i></i>	477
<i> <i>Human retinal pigmented epithelial cells</i></i>	477
<i>Enhancement of growth of stem cells in the brain by drugs</i>	478
<i> <i>C3-induced differentiation and migration of NPC for repair of the brain</i></i>	478
<i>Stem cell therapies of neurological disorders combined with HBO.....</i>	479
<i>hESCs for CNS repair.....</i>	479
<i>Motor neurons derived from stem cells</i>	479
<i>MSCs for CNS repair.....</i>	480
<i>Neuronal differentiation of stem cells.....</i>	481
<i> <i>Apigenin promotes differentiation of stem cells into neural lineage</i></i>	481
<i>Stem cells preparations for CNS disorders.....</i>	481
<i>Tracking of stem cells in the CNS by nanoparticles and MRI</i>	482
<i>Use of neural stem cells to construct the blood brain barrier.....</i>	483
<i>Methods of delivery of cells to the CNS</i>	483
<i> <i>Cerebrospinal fluid-stem cell interactions for therapy of CNS disorders</i></i>	483
<i> <i>CNS delivery of cells by catheters</i></i>	484
<i> <i>Engineered stem cells for drug delivery to the brain</i></i>	484
<i> <i>Encapsulated cells.....</i></i>	484
<i> <i>Intrathecal delivery of stem cells</i></i>	485
<i> <i>Intraparenchymal delivery of stem cells to the spinal cord</i></i>	485
<i> <i>Intravascular administration.....</i></i>	486
<i> <i>Neural stem cells as therapeutic delivery vehicles</i></i>	486
Neurological disorders amenable to cell therapy	486
<i>Neuroprotection by cell therapy</i>	487
<i> <i>Cells secreting neuroprotective substances.....</i></i>	487
<i> <i>Stem cells for neuroprotection</i></i>	487

<i>Neuroprotection by intravenous administration of HSCs</i>	487
<i>Human UCB-derived stem cells for the aging brain.....</i>	488
<i>Neurodegenerative disorders.....</i>	488
<i>MSCs for therapy of neurodegenerative disorders</i>	488
<i>Role of stem cells in neurodegenerative disorders</i>	489
<i>Role of NSCs in disorders associated with aging brain.....</i>	490
<i>NSCs for improving memory.....</i>	490
<i>Parkinson's disease</i>	491
<i>Cell therapies for PD.....</i>	491
<i>Delivery of cells for PD.....</i>	493
<i>Dopamine neurons for PD</i>	493
<i>Encapsulated cells for PD</i>	494
<i>Graft survival-enhancing drugs</i>	494
<i>hiPSCs for personalized restoration of motor function in PD.....</i>	495
<i>Human retinal pigment epithelium cells for PD.....</i>	495
<i>Potential of regeneration of endogenous stem cells in PD</i>	496
<i>Pluripotent stem cell-derived neurons.....</i>	496
<i>Stem cell transplantation in animal models of PD</i>	497
<i>Stem cells for production of glial derived neurotrophic factor</i>	499
<i>Transplantation of embryonic medial ganglionic eminence cells.....</i>	499
<i>Trials of stem cell transplantation in PD patients</i>	500
<i>Tumorigenic potential of transplanted dopaminergic hESCs</i>	501
<i>Xenografting porcine fetal neurons.....</i>	501
<i>Personalized stem cell therapy for PD</i>	502
<i>Future perspectives of clinical trials of stem cell therapy for PD</i>	502
<i>MSCs for multiple system atrophy</i>	502
<i>Cell therapy for Huntington's disease.....</i>	503
<i>Fetal striatal cell transplantation</i>	503
<i>Transplantation of encapsulated porcine choroids plexus cells.....</i>	503
<i>iPSCs for HD.....</i>	504
<i>Mobilization of endogenous neural progenitor cells in HD</i>	504
<i>Cell therapy for Alzheimer's disease</i>	504
<i>Choroid plexus epithelial cells for AD</i>	505
<i>Implantation of genetically engineered cells producing NGF.....</i>	505
<i>Neural stem cell implantation for Alzheimer's disease</i>	505
<i>Use of autologous stem cells for dementia</i>	506
<i>Cell therapy for amyotrophic lateral sclerosis.....</i>	506
<i>Stem cell techniques for study of ALS.....</i>	507
<i>Rational for use of stem cells for ALS.....</i>	507
<i>Experimental studies with various types of stem cells for ALS</i>	508
<i>Clinical trials of stem cells for ALS.....</i>	509
<i>Transplantation of glial restricted precursors in ALS</i>	510
<i>Stem cell-based drug discovery for ALS</i>	510
<i>Cell therapy for demyelinating disorders</i>	511
<i>Autologous bone marrow stem cell therapy for multiple sclerosis</i>	511
<i>ESCs for remyelination</i>	512
<i>Fusokine method of personalized cell therapy of MS</i>	512
<i>Genetically engineered macrophages expressing NaV1.5.....</i>	512
<i>Hematopoietic stem cell transplantation for MS.....</i>	513
<i>MSCs for multiple sclerosis.....</i>	513
<i>Neural progenitor cells for neuroprotection in MS</i>	514
<i>NSC transplantation for repair of demyelination after</i>	514
<i>iNSCs for antiinflammatory effect in MS</i>	515
<i>Oligodendrocyte generation from human iPSCs.....</i>	515
<i>T cell-based personalized vaccine for MS.....</i>	515
<i>T cell-directed therapies for MS</i>	515
<i>Stem cells for chronic inflammatory demyelinating polyneuropathy</i>	516
<i>Stem cell transplantation for Pelizaeus-Merzbacher disease</i>	516
<i>X-linked adrenoleukodystrophy</i>	516
<i>Cell therapy of stroke</i>	516
<i>Adult stem cell therapy in stroke.....</i>	517
<i>Cell therapy of intracerebral hemorrhage</i>	518
<i>Functional integration of iPSC-derived neurons in stroke-injured brain.....</i>	518
<i>Implantation of genetically programmed ESCs</i>	519
<i>Intravenous infusion of MSCs</i>	519
<i>Intravenous infusion of human UCB stem cells.....</i>	519
<i>Intravenous MSCs to prevent rupture of experimental aneurysms.....</i>	520
<i>Intracerebral administration of human adipose tissue stromal cells</i>	521
<i>Neural stem cell therapy for stroke</i>	521
<i>Preconditioning with hyperbaric oxygen for stem cell therapy</i>	522
<i>Transplantation of encapsulated porcine choroids plexus.....</i>	522

<i>Transplantation of fetal porcine cells</i>	522
<i>Role of cell therapy in management of stroke according to stage</i>	523
<i>Clinical trials of cell therapy for stroke</i>	523
<i>Future of cell therapy for stroke</i>	524
Cell therapy of traumatic brain injury	525
<i>Cell/gene therapy for TBI</i>	526
<i>Clinical trials of autologous stem cell therapy for TBI</i>	526
<i>Limitations of stem cell therapy for acute TBI</i>	527
<i>Improving the microenvironments of transplanted cells in TBI</i>	527
<i>MSC-derived exosomes for treatment of TBI</i>	528
Cell therapy for spinal cord injury	528
<i>Autoimmune T cells against CNS myelin-associated peptide</i>	529
<i>Fetal neural grafts for SCI</i>	529
<i>Olfactory-ensheathing cells for SCI</i>	529
<i>Oligodendrocyte precursor cells for treatment of SCI</i>	529
<i>Schwann cell transplants for SCI</i>	530
<i>Transplantation of glial cells for SCI</i>	530
Stem cells for SCI	530
<i>Bone marrow stem cells for SCI</i>	531
<i>Embryonic stem cells for SCI</i>	531
<i>ESC-derived neural aggregates for treatment of SCI</i>	532
<i>Transplantation of induced pluripotent stem cells in SCI</i>	532
<i>Transplantation of MSCs for SCI</i>	532
<i>Transplantation of NSCs for SCI</i>	533
<i>Transplantation of human dental pulp stem cells</i>	534
<i>Transdifferentiation of BM stem cells into cholinergic neurons for SCI</i>	534
<i>Evaluation of experimental studies of stem cell transplantation in SCI</i>	534
Spinal stem cells for treatment of ischemic injury of spinal cord.....	535
Combined approaches for regeneration in SCI	535
<i>Combined cell/gene therapy for SCI</i>	535
Delivery of cells in SCI.....	536
<i>Intrathecal injection of cells labeled with magnetic nanoparticles</i>	536
<i>Intravenous injection of stem cells for spinal cord repair</i>	536
Clinical applications of stem cells for SCI.....	537
<i>Autologous bone marrow cell transplantation for SCI</i>	537
<i>Cell therapy of syringomyelia</i>	537
Cell therapy for neurogenetic disorders.....	537
<i>Hurler's syndrome treated with stem cells</i>	538
<i>Krabbe's disease treated with UCB stem cells</i>	538
<i>Krabbe's disease treated with combination of cell and gene therapy</i>	539
<i>Mitochondrial encephalopathies treated with stem cells</i>	539
<i>Sanfilippo syndrome type B treated with UCB stem cells</i>	540
Cell therapy for lysosomal storage disorders.....	540
<i>Cell therapy for Batten disease</i>	540
<i>Cell/gene therapy for Farber's disease</i>	541
<i>Genetically modified HSCs for metachromatic leukodystrophy</i>	541
<i>Neural stem cells for lysosomal storage disorders</i>	541
Cell therapy of epilepsy	542
<i>Cell therapy of posttraumatic epilepsy</i>	542
<i>Cell therapy for temporal lobe epilepsy</i>	542
<i>Cell therapy for pharmacoresistant epilepsies</i>	543
Cell therapy for developmental neurological disorders	543
Cell therapy for cerebral palsy	543
Cell-based therapies for malignant CNS tumors	544
<i>Bone morphogenetic protein for inhibition of glioblastoma</i>	544
<i>CAR-T cell therapy of glioblastoma</i>	545
<i>Dendritic cell therapy for brain tumors</i>	545
<i>Encapsulated cells for brain tumors</i>	546
<i>Engineered human NSCs for treatment of spinal cord gliomas</i>	546
<i>Immunotherapy of glioblastoma targeting cancer stem cells</i>	546
<i>Mesenchymal stem cells for the treatment of gliomas</i>	547
<i>Neural stem cells for treatment of malignant brain tumors</i>	547
<i>Role of cancer stem cells in resistance to radiotherapy</i>	549
<i>Stem cell-based therapy targeting EGFR in glioblastoma</i>	550
<i>Targeting stem cells in brain tumors</i>	550
<i>Clinical trials of cell therapy of glioblastoma</i>	550
Cell therapy for chemobrain	550
Cell therapy for muscle disorders	551
<i>Duchenne muscular dystrophy</i>	551
<i>Combination of cell and pharmacotherapy for DMD</i>	552
<i>Myoblast transplant for DMD</i>	552

<i>Myoblast-based gene transfer</i>	552
<i>Myoblasts lacking the MyoD gene</i>	553
<i>Myoblast injection for treatment of other muscular dystrophies</i>	553
<i>Role of satellite cells in the treatment of DMD</i>	553
<i>Stem cells for DMD</i>	554
<i>Wnt7a treatment for DMD</i>	555
Cell therapy for autism	556
Management of chronic intractable pain by cell therapy	556
<i>Implantation of chromaffin cells</i>	557
<i>Role of stem cells in management of pain</i>	557
<i>Implantation of astrocytes secreting enkephalin</i>	557
<i>Cells for delivery of antinociceptive molecules</i>	558
<i>Implantation of genetically engineered cells</i>	558
<i>Cell therapy for low back pain</i>	558
Cell therapy for neuropathic itch	559
Cell therapy for neuroendocrine disorders	559
<i>Pituitary stem cells</i>	559
Cell therapy for regenerating optic pathways.....	559
Cell therapy for retinal degenerative disorders.....	560
<i>Delivery of CNTF by encapsulated cell intraocular implants</i>	560
<i>Genetically engineered retinal pigmented epithelial cell lines</i>	561
Stem cell-based therapies for retinal degenerative disorders	561
<i>Adipose-derived stem cells for retinal degeneration</i>	561
<i>Adipose-derived stem cells transplantation for diabetic retinopathy</i>	562
<i>ESCs for retinal degenerative disorders</i>	562
<i>hESC-derived RPE cells for AMD</i>	562
<i>Human retinal stem cells</i>	563
<i>iPSCs for AMD</i>	564
<i>Neuroprotective effect of neural progenitor cell transplantation</i>	564
<i>Stem-cell based therapy for retinitis pigmentosa</i>	565
<i>Stem cell transplantation in the retina</i>	565
<i>Combining stem cell and gene therapies for retinal disorders</i>	566
Clinical trials of cell therapy for retinal degenerative disorders	566
Stem cell therapy for hearing loss	567
Cell theory for peripheral nerve lesions.....	568
<i>Cell transplants for peripheral nerve injuries</i>	568
<i>Role of adipose-derived stem cells in peripheral nerve regeneration</i>	568
<i>Treatment of diabetic neuropathy with endothelial progenitor cells</i>	568
Complications of cell therapy of neurological disorders	569
Tumor formation after CNS transplantation of stem cells.....	569
<i>Donor stem cell-derived brain tumor</i>	569
<i>Glioproliferative lesion of spinal cord as a complication of cell therapy</i>	569
<i>Uncontrolled differentiation of implanted ESCs</i>	569
Tumorigenicity of ESC-derived retinal progenitor cells	570
Clinical trials of cell therapy in neurological disorders	570
Future of cell therapy of CNS disorders	572
8. Ethical, Legal and Political Aspects of Cell therapy	573
Introduction	573
Political and ethical aspects of hESC research in the US	573
Ethical issues concerning fetal tissues.....	574
<i>Morality and hESC research</i>	574
Opponents of hESC research in the US	574
<i>Use of hESCs in NIH-supported research</i>	576
<i>Politics of hESC research in the US</i>	576
<i>Public opinion in the US about hESC research</i>	578
<i>Human stem cell cloning in the US</i>	580
<i>Stem cell guidelines of various US institutions</i>	580
Ethics of transplanting human NSCs into the brains of nonhuman primates	581
Public opinion on use of iPSCs for growing human organs in animals	581
Stem cell research around the world	582
ESC lines available worldwide.	582
ESC policies around the world.	583
Countries with no defined policies on hESC research	584
Australia	584
Canada.....	585
China	585
Denmark	586
France.....	587
Germany	587
India	588

Ireland	589
Israel	589
Italy	590
Japan	590
Russia	592
The Netherlands	592
Saudi Arabia.....	592
Singapore.....	592
South Africa	593
South Korea.....	593
Spain	594
Sweden	594
Switzerland	594
United Kingdom	595
<i>UK StemCellBank</i>	596
European Union	596
<i>EU guidelines for stem cell research</i>	596
<i>European stem cell bank</i>	598
<i>EMBO's recommendations for stem cell research</i>	598
Public opinion in Europe about hESC research.....	599
United Nations, cloning and nuclear transfer.....	600
The Embryo Project for information on ESC research	600
Concluding remarks about ethics of ESC research	601
Ethical issues concerning umbilical cord blood	601
Legal issues associated with stem cells	601
Stem cell patents	601
<i>Stem cell patents in the United States</i>	601
<i>Current status of Thomson patents at WARF</i>	602
<i>Stem cell patents in the European Union</i>	603
Cell therapy tourism	603
9. Safety and Regulatory Aspects of Cell Therapy	605
Introduction	605
Safety issues of cell therapy	605
Immune-mediated reactions to transplanted stem cells	605
Human virus infections associated with stem cell transplantation	606
<i>Herpes simplex virus type 1</i>	606
<i>Cytomegalovirus</i>	606
Opportunistic infections among hematopoietic stem cell transplant recipients	606
Cord colitis syndrome	606
Carcinogenic potential of stem cells and its prevention	607
Regulatory challenges for the clinical use of cell products.....	607
Prediction of in vivo performance of cell-based therapies	608
FDA safety regulations for cell and tissue products	608
FDA Guidance on license applications for umbilical cord blood products.....	609
Regulation of cord blood banks in the US	609
Regulatory issues for biotechnology-derived drugs	609
Regulation of products for adoptive cell therapy of cancer	610
Regulation of cell selection devices for PBSCs at point of care	610
FDA rules for human cells and tissues	611
FDA regulation of fetal cellular or tissue products.....	612
<i>FDA and ESC lines</i>	612
FDA and clinical trials using hESCs	612
Cell and gene therapies approved by the FDA.....	613
Cell and gene therapy INDs placed on hold by the FDA	614
Regulatory issues for genetically engineered cell transplants	614
FDA guidelines for human tissue transplantation	614
FDA considers cultured stem cells for therapy as drugs.....	615
FDA perspective on safety-efficacy and risk-benefit of stem cell therapy	615
FDA action against unapproved cell therapy in the US	617
Xenotransplantation	619
Clinical Protocol Review and Oversight.....	619
Informed consent and patient education	619
Xenotransplantation product sources	620
FDA guidelines for xenografts	620
US regulations for manufacture of cell therapy products	622
<i>GMP in USA</i>	623
Regulations relevant to cell therapy in the European Union.....	623
Regulations about use of stem cells in the EU	625
Guidelines for cell therapy in the UK.....	625
Quality requirements for ex vivo-expanded MSC products for clinical use	626

European regulations for manufacture of cell therapy products	626
<i>GMP in Europe</i>	626
Global regulation of stem cell approval.....	627
Transport of stem cells between countries	627
Temperature limitations during transport of stem cells	627
NIH and stem cells.....	627
hESC lines approved under the new NIH guidelines	627
Clinical trials in cell therapy.....	628
Assessment of clinical trial registration and publication	628
Misuse of listing on ClinicalTrials.gov to provide unapproved stem cell therapy	629

Tables

Table 1-1: Landmarks in the history of cell therapy	31
Table 1-2: Examples of cells involved in various diseases	37
Table 2-1: Types of human cells used in cell therapy.....	43
Table 2-2: A selection of companies providing cell culture media	49
Table 2-3: A sampling of companies supplying cell sorters	55
Table 2-4: Companies involved in cell-based drug discovery	64
Table 2-5: Methods of delivery of cells for therapeutic purposes	67
Table 2-6: Therapeutic applications of encapsulated cells.....	73
Table 2-7: Companies working on encapsulated cell technology.....	74
Table 2-8: Molecular imaging methods for tracking cells in vivo	80
Table 3-1: Various levels of potency relevant to stem cells	88
Table 3-2: Clinical trials of UCB	115
Table 3-3: Companies involved in cord blood banking as a source of stem cells	118
Table 3-4: Comparison of techniques for nuclear reprogramming of stem cells	123
Table 3-5: Banks of patient-specific iPSC lines.....	128
Table 3-6: Companies providing iPSCs	129
Table 3-7: Sources of adult human stem cells	135
Table 3-8: Comparison of human stem cells according to derivation.....	146
Table 3-9: Enhancing engraftment, mobilization and expansion of stem cells	165
Table 3-10: Applications of stem cells	183
Table 3-11: Advantages and limitations of methods for optimizing MSCs	196
Table 3-12: Pharmaceutical manipulation of stem cells	202
Table 3-13: Growth factors with positive effects on stem cells and applications	203
Table 3-14: Examples of drugs that induce granulocytopenia at stem cell level.....	215
Table 3-15: Academic institutes involved in stem cell research	223
Table 3-16: Companies involved in stem cell technologies	225
Table 4-1: Therapeutic applications of regulatory T cells (Tregs).....	244
Table 4-2: Various tissue/cell therapy approaches to the treatment of type 1 diabetes	253
Table 4-3: Companies involved in cell therapy for insulin-dependent diabetes	270
Table 4-4: Major pulmonary disorders potentially treatable by stem cell manipulation	290
Table 4-5: Clinical trials of MSCs in COPD	293
Table 4-6: Cell-based repair of knee cartilage damage	308
Table 4-7: Intraoperative cell therapy	343
Table 5-1: Classification of various types of cell therapy for cardiovascular disorders	348
Table 5-2: Clinical trials of cell therapy in cardiovascular disease	389
Table 6-1: Cell therapy technologies used for cancer	397
Table 6-2: Companies developing CAR-T cell therapy	419
Table 6-3: Companies involved in developing cell-based therapies for cancer	448
Table 7-1: Studies in rats or mice of in vivo reprogramming of cells for brain repair.....	455
Table 7-2: NSCs-based approaches for neurological disorders	469
Table 7-3: Experimental use of immortalized cells for CNS disorders	473
Table 7-4: Combination of stem cells and HBO in models of neurological disorders	479
Table 7-5: Therapeutic applications of MSCs for neurological disorders.....	480
Table 7-6: Methods for delivering cell therapies in CNS disorders.....	483
Table 7-7: Neurological disorders amenable to cell therapy	486
Table 7-8: Types of cell used for investigative treatment of Parkinson's disease	491
Table 7-9: Status of cell therapies for Parkinson's disease	492
Table 7-10: Role of cell therapy in management of stroke according to stage	523
Table 7-11: Clinical trials of cell therapy for stroke: completed, ongoing and pending	523
Table 7-12: Clinical trials of cell therapy for retinal degenerative disorders	566
Table 7-13: Clinical trials with cell therapy in neurological disorders (excluding stroke)	570
Table 8-1: Listed numbers of ESC lines around the world	583
Table 8-2: Stem cell policies around the world	583
Table 8-3: European public attitudes about research involving human stem cells	599
Table 9-1: Possible adverse reactions and safety issues of cell therapy.....	605
Table 9-2: Cell and gene therapies approved by the FDA	613

Figures

Figure 1-1: Interrelationships of cell therapy to other technologies	34
Figure 1-2: Interrelationships of gene, cell and protein therapies	35
Figure 1-3: Engineering of RBCs for drug delivery.....	40
Figure 3-1: A simplified biological scheme of embryonic stem Cells	88
Figure 3-2: Steps of iPS cell production	124
Figure 3-3: hESC-derived by somatic cell nuclear transfer	162
Figure 3-4: Approaches for optimizing preparation of HSCs for transplantation.....	185
Figure 3-5: Flow chart of development of stem cells with potential bottlenecks.....	230
Figure 4-1: Reprograming ESCs/IPSCs cells to β -cells for type 1 diabetes	265
Figure 4-2: Fluorescently labeled polarized Upcyte® hepatocytes	274
Figure 5-1: Ex vivo vs in vivo approaches to regeneration of the heart	348
Figure 5-2: hESC-derived cardiomyocytes from laboratory to bedside	363
Figure 5-3: Steps in growing a new heart in vitro for transplantation.....	385
Figure 6-1: A scheme of generation and administration of tumor antigen-pulsed dendritic cells	407
Figure 6-2: Chimeric antigen receptor (CAR)-T cells attacking tumor cells.....	414
Figure 6-3: Stem cell transplantation techniques	427
Figure 7-1: Cell-based methods for repair of the brain.....	452
Figure 7-2: Reprogramming methods for in vivo generation of neurons.....	453
Figure 7-3: Stem cells that can give rise to neurons.....	463
Figure 7-4: Sources of dopaminergic neurons for transplantation in Parkinson's disease	493
Figure 7-5: hiPSCs for restoring motor function in PD.....	495
Figure 7-6: Scheme of iPSCs for personalized cell therapy of Parkinson disease.....	502
Figure 7-7: Potential mechanisms of stem cell efficacy in ALS	507
Figure 7-8: Approaches to stem cell therapy in stroke	518
Figure 8-1: Global stem cell publications 2015-2019	582